Exercise and Nutrition Intervention in Ovarian Cancer

6 Minute Walk Test (distance in metre)

Sub-maximal exercise test used to assess aerobic capacity and endurance

Time frame: Change in the total distance from T1 (end of chemotherapy, approx. week 18-19) to baseline as target

Global physical activity questionnaire (GPAQ)

Physical activity in minutes per day, MET minutes per week

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Assessment of body composition using bioelectrical impedance analysis (BIA)

Bioelectrical impedance analyzers use an alternating electric current to measure the two components of bioelectrical impedance in the human body, resistance r and reactance Xc. In electrophysiological terms, resistance (per unit volume) correlates negatively with the amount of body fluid (body water and fat-free mass (FFM)) through which the current flows, while reactance correlates positively with the mass of body cells. The magnitude of Xc in relation to R is expressed as the phase angle (PA). From the measured R and Xc values and other subject data, additional indicators of body composition (e.g., total body water, fat-free mass, and fat mass) can be estimated using specific prediction equations based on modeling assumptions that are generally population-, age-, sex-, fat-, and disease-specific.

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Grip force dynamometer

Hand gripping force (kg)

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Polyneuropathy; item derived from EORTC CIPN20 (Item 9)

Problems standing or walking, because can't longer feel the ground under feet

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Patient Health Questionnaire-9 (PHQ-9)

Depression screening

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Generalized Anxiety Disorder using GAD-2

Anxiety

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Adherence to a Mediterranean diet (MEDAS)

Adherence to a Mediterranean diet is assessed using the 14-item Mediterranean Diet Adherence Screener (MEDAS).

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

EORTC QLQ-C30

Quality of life (multidimensional) across 10 subscales

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

EORTC OV-28

Quality of life (multidimensional) focusing on ovarian cancer across 7 subscales

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

EORT FA-12

Quality of life (multidimensional) focusing on fatigue

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Nutritional Risk Screening (NRS 2002)

Malnutrition risk

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Brief Social Support Scale (BS6)

Social support (tangible support, emotional-informational support)

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

Patient Activation Measure (PAM-13)

Patient Activation Measure

Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))